Mumbai, June 3 -- The approved product is bioequivalent to Halaven Injection, the reference-listed drug (RLD) marketed by Eisai Inc.

Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously undergone at least two chemotherapy regimens for metastatic disease. It is also used for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

According to IQVIA MAT data for April 2026, the reference drug Halaven recorded estimated annual sales of approximately $43.7 million in the United States.

NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceut...